10x Genomics Inc (TXG) concluded trading on Thursday at a closing price of $9.95, with 4.05 million shares of worth about $40.34 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -53.53% during that period and on March 20, 2025 the price saw a loss of about -3.30%. Currently the company’s common shares owned by public are about 108.24M shares, out of which, 101.42M shares are available for trading.
Stock saw a price change of 0.71% in past 5 days and over the past one month there was a price change of -17.77%. Year-to-date (YTD), TXG shares are showing a performance of -30.71% which decreased to -72.42% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $9.27 but also hit the highest price of $39.30 during that period. The average intraday trading volume for 10x Genomics Inc shares is 2.62 million. The stock is currently trading -7.39% below its 20-day simple moving average (SMA20), while that difference is down -22.66% for SMA50 and it goes to -41.73% lower than SMA200.
10x Genomics Inc (NASDAQ: TXG) currently have 108.24M outstanding shares and institutions hold larger chunk of about 79.43% of that.
The stock has a current market capitalization of $1.22B and its 3Y-monthly beta is at 1.95. It has posted earnings per share of -$1.52 in the same period. It has Quick Ratio of 4.26 while making debt-to-equity ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TXG, volatility over the week remained 4.68% while standing at 7.27% over the month.
Stock’s fiscal year EPS is expected to rise by 1.75% while it is estimated to increase by 22.96% in next year. EPS is likely to grow at an annualized rate of 17.47% for next 5-years, compared to annual growth of -36.10% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on February 13, 2025 offering a Market perform rating for the stock and assigned a target price range of between $25 and $12 to it. Coverage by Leerink Partners stated 10x Genomics Inc (TXG) stock as an Outperform in their note to investors on September 03, 2024, suggesting a price target of $35 for the stock. On July 22, 2024, Jefferies Upgrade their recommendations, while on July 18, 2024, JP Morgan Downgrade their ratings for the stock with a price target of $20. Stock get a Hold rating from Deutsche Bank on July 10, 2024.
